Skip to content
Medical Health Aged Care, Women

Pregnant women might not be receiving nicotine replacement therapy long enough to quit smoking: study

NDARC 3 mins read

A global study reveals how many women use pharmacotherapies to quit smoking during pregnancy, noting possible gaps in support.

Maternal use of quit smoking medicine aligns with current clinical advice, but low completion rates of nicotine replacement therapy (NRT) may mean that pregnant women need more support to successfully quit smoking, a review of prescription medicine data has revealed.

The UNSW-led population-wide study – published in JAMA Network Open today – aimed to find out how many pregnant women were using quit smoking medicines. Researchers looked at data for everyone giving birth over a five-year period in four countries: 1.7 million pregnancies in Australia (NSW only), New Zealand, Norway and Sweden.

“Smoking during pregnancy is one of the main causes of adverse pregnancy outcomes,” says Dr Annelies Robijn, study lead author and pharmacoepidemiologist at UNSW Sydney’s National Drug and Alcohol Research Centre (NDARC).

“Quitting smoking during pregnancy can reduce the risk of negative outcomes. Up-to-date data about how many women are using medicines to assist them to quit smoking is necessary to understand where we can make improvements.

“While there is some data on smoking cessation pharmacotherapy use during pregnancy, it’s outdated. Our goal with this study was provide evidence of what’s happening currently in practice and compare this to the clinical guidelines.”

Medicines are the most effective way to quit smoking in general population

Quit smoking medicines like varenicline, NRT and bupropion are considered the most effective smoking cessation strategy in the general population. However, whether they are effective and safe for use in pregnancy is not well studied.

“While the clinical guidelines suggest counselling as the first approach for quitting smoking during pregnancy, evidence for psychosocial interventions like counselling to help quit smoking is not very encouraging,” says Dr Robijn.

“Pharmacotherapies or medicines, specifically NRT, are the second line of treatment for pregnancy, and we know that medicines are the most effective strategy available to help people who are not pregnant quit smoking.”

Varenicline is a tablet designed specifically for smoking cessation, while bupropion is a type of antidepressant that can also be used for smoking cessation. NRT, on the other hand, involves patches, lozenges and gums. 

“Patches, lozenges and gums are preferable to varenicline and bupropion as there are fewer concerns about the safety of NRT in pregnancy.”

Uptake of nicotine replacement therapy during pregnancy low or incomplete

Prescription NRT was used by less than 2% of women in New Zealand. More specifically, among women who smoked during pregnancy, one in 10 used prescription NRT.

There was minimal use of prescription NRT in the other countries, where NRT is potentially more often purchased without a prescription.

Among the women who did use prescription NRT, the majority did not take NRT long enough for a successful quit attempt.

“The research findings highlight the need for robust information about safety and effectiveness regarding the use of NRT during pregnancy,” says Dr Robijn.

“Armed with better knowledge, pregnant women and clinicians can make informed choices around quitting smoking during pregnancy. Our team at NDARC is continuing to work with our collaborators in New Zealand, Norway and Sweden to providing this much-needed evidence.”

Safety of varenicline and bupropion needs further evaluation 

The study provides reassurance regarding the use of varenicline and bupropion.

“Due to limited evidence of their safety, varenicline and bupropion are not recommended for use during pregnancy,” says Dr Robijn.

“Our analysis found a reassuringly low number of women – less than a quarter of a percent – used varenicline or bupropion during pregnancy.”

The low use of varenicline and bupropion aligns with current clinical guidelines and recommendations.

“Further research is urgently needed on the safety of varenicline and bupropion during pregnancy, as they may present a useful alternative for pregnant women wanting to quit smoking.”

More from this category

  • Medical Health Aged Care
  • 23/10/2024
  • 14:43
Dementia Australia

Dementia Australia supports Bridgetown & Nannup

Are you concerned about your memory or worried that someone you know may have dementia? Dementia Australia is offering support in Bridgetown and Nannup between 6 and 8 November. It is estimated there are more than 40,500 people living with all forms of dementia in Western Australia. Without a medical breakthrough this number is expected to increase to almost 87,000 people living with dementia by 2054. These Dementia Australia sessions are an opportunity for people living with dementia, their carers, family, and friends to attend free education to better understand dementia and to discuss the support and services Dementia Australia…

  • Contains:
  • National News Current Affairs, Women
  • 23/10/2024
  • 11:42
Australian Chiropractors Association & Insight Communications

Women’s Workspace Pain Epidemic: WMSDs & Australian Women

Women’s Workspace Pain Epidemic:WMSDs & Australian Women WORKSPACE WEEK 21–27 OCTOBER 2024 – Work Well Everywhere WorkSpace Health is EveryBODY’s Business Work-related Musculoskeletal Disorders…

  • Contains:
  • COVID19, Medical Health Aged Care
  • 23/10/2024
  • 08:55
PSS Distributors

Failed Vaccines Put Thousands of Aussie Lives at Risk and Cost the Government $22 Million in Wastage

The eye-watering cost of vaccine wastage and the serious public health threat posed by compromised vaccines already given to Australians are making headlines across major news outlets right now, underscoring the need for urgent action. The national press reported last week that over 1,200 patients at a general practice in Sydney’s inner west – including hundreds of children receiving their first vaccinations under the age of five –were informed that the vaccines they received between December 2019 and July 2024 may not be fully effective due to improper storage, leaving them prone to serious diseases like polio, hepatitis, meals, whooping…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.